The NCCN Guidelines for MM provide a framework on which to base decisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to relapsed/refractory disease.

Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease. Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia. Are You Applying the Latest Guidelines for Multiple Myeloma? Experts Discuss Equitable, Evidence-Based Care

Based on data from the HOVON-65/GMMG-HD4 trial and the uniform consensus among the NCCN Multiple Myeloma Panel, bortezomib/doxorubicin/dexamethasone is a category 1 option for primary therapy for transplant-eligible patients with MM.

2024年12月20日 · When multiple myeloma causes symptoms, treatment often starts with medicine. Treatment can help relieve pain, control complications, and slow the growth of the myeloma cells. Treatment may not be needed right away

mSMART stands for Stratification for Myeloma and Risk-Adapted Therapy, which are continuously updated Mayo Clinic multiple myeloma treatment approach guidelines. We purposely chose a non-English word — an acronym — for the guidelines, so it would be easily internet searchable.

2019年4月1日 · The purpose of this guideline is to provide evidence-based recommendations for the treatment of newly diagnosed and relapsed multiple myeloma. The treatment of multiple myeloma has changed significantly in the last 5 years.

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. These Guidelines were developed by the European Hematology Association (EHA) and ESMO. The two societies nominated authors to write the guidelines as …

Initial treatment of patients with multiple myeloma who are transplant ineligible should include at minimum a novel agent (immunomodulatory drug or PI) and a steroid if possible (Type: evidence based; Evidence quality: high, benefit outweighs harm; Strength of recommendation: strong).

2021年2月3日 · Key treatment recommendations are provided for both newly diagnosed myeloma patients and patients with relapsed/refractory disease. Recommendations for the treatment of plasma cell leukaemia, solitary plasmacytoma and smouldering myeloma are also provided.

2024年11月2日 · Multiple myeloma (MM) is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia....